Novel Antibody-Drug Conjugate L-DOS47 Shows Safety Profile in Phase I/II NSCLC Trial
核心洞察
L-DOS47, a novel antibody-drug conjugate targeting CEACAM6 (搜索)-expressing tumors, demonstrated safety and tolerability in a Phase I/II trial of 76 non-small cell lung cancer patients at doses up to 13.55 μg/kg.
The drug's unique mechanism involves converting urea to ammonia and bicarbonate at the tumor surface to reverse acidosis in the tumor microenvironment, representing a first-in-class approach to combat tumor acidity.
While no complete or partial responses were observed in monotherapy, exploratory analyses showed median progression-free survival of 4.1 months in the highest dosing quartile, with 93% of these patients having received two or more prior therapies.
A first-in-human Phase I/II clinical trial has demonstrated the safety and tolerability of L-DOS47, an unconventional antibody-drug conjugate designed to combat tumor acidity in non-small cell lung cancer (NSCLC) patients. The multicenter study, conducted across four sites in Poland, enrolled 76 patients with advanced NSCLC and represents the first clinical evaluation of a therapeutic approach specifically targeting tumor microenvironment acidosis.
Novel Mechanism Targets Tumor Acidosis
L-DOS47 represents a departure from conventional antibody-drug conjugates through its unique mechanism of action. The immunoconjugate consists of jack bean urease conjugated to approximately 10 copies of a camelid nanobody that binds with high affinity to CEACAM6 (搜索), a cell adhesion molecule overexpressed in many cancers including NSCLC and pancreatic adenocarcinoma.
Unlike traditional ADCs that internalize and release cytotoxic payloads, L-DOS47 remains on the cell surface where the urease component converts local urea to ammonia and bicarbonate, raising tumor microenvironment pH and reversing acidosis. This approach addresses a fundamental characteristic of solid tumors, which generate hypoxic environments and maintain glycolytic metabolism that causes acid accumulation promoting genetic instability, abnormal lipid metabolism, and metastasis.
Safety Profile Established Across Dose Levels
The Phase I portion of the study employed a standard 3+3 dose escalation design across 16 cohorts, with doses ranging from 0.12 to 13.55 μg/kg administered weekly. Maximum tolerated dose was not reached at the highest tested dose level, with only one dose-limiting toxicity observed - Grade 4 bone pain in a patient receiving 5.76 μg/kg.
Among the 55 Phase I patients, 44 (80%) experienced treatment-emergent adverse events, with respiratory disorders being most common, reported by 21 patients (38%). Dyspnea was reported by 15 patients (27%), though only two cases were assessed as treatment-related. Three patients (5%) experienced infusion reactions consisting of chills, dyspnea, and infusion site reactions, leading to temporary interruptions but not treatment discontinuation.
The safety profile remained consistent in Phase II, where 21 patients received twice-weekly dosing at 13.55 μg/kg. Gastrointestinal events were most common in this phase, experienced by 57% of patients, with nausea and vomiting being most frequently reported. No deaths in either phase were attributed to L-DOS47 treatment.
Limited Efficacy as Monotherapy
While L-DOS47 demonstrated an acceptable safety profile, efficacy as monotherapy was limited. No complete or partial responses were observed in either study phase. However, exploratory analyses in Phase I revealed encouraging signals in heavily pretreated patients. Median progression-free survival in the highest dosing quartile reached 4.1 months, notable given that 93% of patients in this group had received two or more prior therapies.
The apparent short half-life of L-DOS47 prompted investigators to implement twice-weekly dosing in Phase II to potentially improve response rates. Despite this intensified regimen, no objective responses were achieved, leading to discontinuation of monotherapy development in favor of combination approaches.
CEACAM6 Expression Analysis Reveals Patient Selection Opportunity
Post-hoc immunohistochemistry analysis of a tumor microarray comprising 31 NSCLC cases provided crucial insights into CEACAM6 (搜索) expression patterns. High CEACAM6 expression was observed in 45.2% of cases, while 48.4% expressed low to undetectable levels. Good concordance was demonstrated between CEACAM6 expression and L-DOS47 binding (Spearman correlation = 0.535, P = 0.0019).
This analysis highlighted a major study limitation: patients were not screened for CEACAM6 (搜索) expression prior to enrollment. The heterogeneity in tumor CEACAM6 expression may explain the modest efficacy observed, as L-DOS47 requires sufficient target expression to bind and alkalinize the tumor microenvironment.
Combination Therapy Shows Promise
The study's findings have redirected development efforts toward combination approaches. A separate Phase I trial combining L-DOS47 with pemetrexed and carboplatin in NSCLC patients reported promising anti-tumor activity with 41.7% overall response rate and 75% clinical benefit. Patients in that study responded at doses well below the 13.55 μg/kg monotherapy level, suggesting the optimal biological dose may differ from maximum tolerated dose and depend on combination regimen.
An ongoing Phase Ib/II study is evaluating L-DOS47 in combination with doxorubicin for advanced pancreatic cancer patients. Future development may also explore combinations with checkpoint inhibitors, given preclinical evidence that reversing tumor acidosis can enhance immune system function.
Implications for Future Development
The study establishes several key principles for future L-DOS47 development. Medium to high CEACAM6 (搜索) expression will be required as an eligibility criterion for subsequent trials. Development of a companion diagnostic for CEACAM6 expression is underway to identify patients most likely to benefit from treatment.
The research also validates the concept of targeting tumor microenvironment acidosis as a therapeutic approach. While direct pH measurement remains challenging in clinical settings, potential surrogate markers under consideration include FDG-PET and specialized PET scans to assess CD8+ T-cell tumor infiltration as measures of immune system reactivation.
Despite the lack of monotherapy efficacy, L-DOS47's unique mechanism of action and acceptable safety profile position it as a potentially valuable component of combination regimens for CEACAM6 (搜索)-expressing tumors, representing a novel approach to modifying the tumor microenvironment to enhance anti-cancer therapy effectiveness.